title: Population pharmacokinetic and pharmacodynamic analysis of tremelimumab in patients with metastatic melanoma.
abstract: Tremelimumab, a fully human monoclonal antibody specific for human cytotoxic T-lymphocyte-associated antigen 4, has been studied in clinical trials. We have reported the results of population pharmacokinetics for tremelimumab in 654 metastatic melanoma patients. Population estimates (inter-individual variability [IIV]) for pharmacokinetic parameters in a final model were clearance (CL), 0.26 L/day (31.8%) and central volume of distribution, 3.97 L (20.4%). CL was faster in males, patients with higher values of creatinine clearance and endogenous immunoglobulin, and patients with relatively poor baseline prognostic factors. No dose adjustment was needed based on the magnitude of the change of CL (<30%). The association of CL and overall survival (OS) was investigated. In a Phase 3 trial evaluating tremelimumab as first-line-treatment, median OS for the 147 patients in the fast-CL group (≥ median CL value) was 9.6 months versus 15.8 months for the 146 patients in the slow-CL group (<median CL value). Multiple Cox proportional hazard regression models were constructed to evaluate the association between CL and OS adjusting for the effects of baseline prognostic covariates between two CL groups. The analysis showed statistically significant association between CL and OS (P < .05). Results suggest that higher or more frequent dosing should be considered in future trials.
authors.affiliation: Pfizer Oncology, La Jolla, CA, USA.
authors.forename: Erjian
authors.initials: E
authors.lastname: Wang
authors.forename: Dongwoo
authors.initials: D
authors.lastname: Kang
authors.forename: Kyun-Seop
authors.initials: KS
authors.lastname: Bae
authors.forename: Margaret A
authors.initials: MA
authors.lastname: Marshall
authors.forename: Dmitri
authors.initials: D
authors.lastname: Pavlov
authors.forename: Kourosh
authors.initials: K
authors.lastname: Parivar
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D008954:Models, Biological; D009362:Neoplasm Metastasis; D011379:Prognosis; D016016:Proportional Hazards Models; D012737:Sex Factors; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D015996:Survival Rate; D014018:Tissue Distribution; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C520704:tremelimumab
keywords: drug clearance; malignancy; melanoma; overall survival; population pharmacokinetic; tremelimumab